e-therapeutics integrates computational power and biology to accelerate the discovery of life-transforming RNAi medicines.
We have developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology, to fully capture and interrogate human disease complexity. Using our a proprietary GalNAc-siRNA gene silencing technology, we are harnessing internal target gene discoveries to build an in-house pipeline of next-generation RNAi based medicines.
We believe that e-therapeutics offers a differentiated strategy, with the ability to silence any gene in the liver with extremely rapid pre-clinical timelines, coupled with powerful computational capabilities, including in hepatocyte biology. We look forward to the future with great excitement.
Chief Executive Officer